Cellectar Biosciences, Inc.
CLRB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $14 | $54 | $16 | $37 |
| - Cash | $23 | $10 | $20 | $36 |
| + Debt | $0 | $1 | $1 | $0 |
| Enterprise Value | -$9 | $45 | -$3 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$51 | -$39 | -$29 | -$24 |
| % Margin | – | – | – | – |
| Net Income | -$45 | -$43 | -$32 | -$24 |
| % Margin | – | – | – | – |
| EPS Diluted | -41.89 | -104.988 | -135.179 | -130.353 |
| % Growth | 60.1% | 22.3% | -3.7% | – |
| Operating Cash Flow | -$48 | -$32 | -$25 | -$23 |
| Capital Expenditures | -$0 | -$1 | -$0 | -$0 |
| Free Cash Flow | -$48 | -$33 | -$25 | -$23 |